CVI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CVR Energy is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a mixed setup: price is near short-term support but momentum is not firmly bullish, analysts remain mostly negative, and there is no fresh company news or earnings catalyst to justify an aggressive entry. For an inpatient investor, this is better treated as a hold rather than an immediate buy.
The technical picture is neutral to slightly weak. CVI closed at 33.34 after a modest daily decline from 33.62, while the broader market was up, which shows relative softness. MACD histogram is -0.24 and still below zero, though it is contracting, suggesting bearish momentum is fading but not yet reversed. RSI_6 at 57.2 is neutral, indicating no overbought or oversold condition. Moving averages are converging, which usually signals a pending directional move but not a confirmed breakout. Key levels: pivot 32.95, support 31.20, resistance 34.69. Price is sitting just above the pivot, so the stock is not in a clear buy zone with strong momentum. The modeled trend probabilities are decent over the next week and month, but the immediate trend is still mixed.
The stock also has a favorable option sentiment tilt. The recent probability model suggests better odds of gains over the next week and month, which supports some upside potential if momentum improves.
Analyst stance remains mostly bearish, with multiple Underperform or Sell ratings still in place. Goldman Sachs initiated with a Sell rating and $30 target, and Mizuho/Scotiabank both kept Underperform despite raising targets. There is no recent news catalyst from the past week, and no congress trading data or influential insider buying signal to support a stronger conviction. The latest price action is not showing decisive upside follow-through.
Financial snapshot data was unavailable due to an error, so the latest quarter financials cannot be assessed directly. Because no season or quarterly results were provided, there is no reliable basis here to judge recent revenue, earnings, or margin growth trends from the supplied data.
Analyst sentiment is still negative overall, but target prices have been gradually moving up. Mizuho raised its target to $35 and Scotiabank to $28, yet both kept Underperform ratings. Goldman Sachs also remains bearish with a Sell rating and a $30 target. Raymond James was the only recent positive shift, upgrading to Market Perform from Underperform. Wall Street's pros view is that CVR can benefit from stronger refining margins and improved commodity conditions, but the cons view is that valuation is already fair to rich and the company still needs better leverage, execution, and capital allocation progress before the stock deserves a stronger rating.
